Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1693-1702

  Chamberlain, C ^a   Collin, S M ^a   Stephens, P ^b   Donovan, J ^a   Bahl, A ^c   Hollingworth, W ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IQVIA   (United States)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

cancer drugs fund; chemotherapy; cost effective; NICE; UK

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; IMATINIB; LAPATINIB; LENALIDOMIDE; PANITUMUMAB; PAZOPANIB; RITUXIMAB; SORAFENIB; SUNITINIB;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG UPTAKE; FUNDING; HUMAN; PRESCRIPTION; UNITED KINGDOM; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; GOVERNMENT; HEALTH CARE DELIVERY; NEOPLASMS; PROCEDURES; PURCHASING; RESOURCE ALLOCATION; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; TIME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENGLAND; GOVERNMENT AGENCIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS; RESOURCE ALLOCATION; TIME FACTORS; VALUE-BASED PURCHASING; WALES;

EID: 84908570727     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.86     Document Type: Article

References (34)

1. Appleby J, Raleigh V, Frosini F, Bevan G, Gao H, Lyscom T (2011) Variations in Health Care. The good, the bad and the inexplicable.
2. Borland S (2013) Welsh patients move to England to get NHS cancer drugs because they're four times less likely to get them than those across the border. Mail Online. http://www.dailymail.co.uk/news/article-2402002/Welsh-patients-England-NHS-cancer-drugs.html.
3. Cancer Research UK (2013) Government announces extension of Cancer Drugs Fund, Cancer News. http://www.cancerresearchuk.org/cancer-info/news/archive/cancernews/2013-09-28-Government-Announces-extensionof-Cancer-Drugs-Fund (accessed 28 September 2013).
4. Coleman M (2007) Not credible: A subversion of science by the pharmaceutical industry. Commentary on 'A glocal comparison regarding patient access to cancer drugs. Annal Oncol 18(suppl 3): 1-75.
5. Crawford SM, Sauerzapf V, Haynes R, Forman D, Jones AP (2012) Social and geographical factors affecting access to treatment of colorectal cancer: A cancer registry study. BMJ Open 2(2): E000410.
6. Department of Health (2010) d50 million kick-starts greater access to cancer drugs. London, Crown Copyright. http://webarchive.nationalarchives.gov. uk/20130107105354/http://www.dh.gov.uk/en/MediaCentre/Pressreleases/DH-120037.
7. Department of Health. 2013 The NHS Constitution. The NHS belongs to us all. Crown Copyright. http://www.nhs.uk/choiceintheNHS/Rightsandpledges/NHSConstitution/Documents/2013/the-nhsconstitution-for-england-2013.pdf.
8. Faden RR, Chalkidou K, Appleby J, Waters HR, Leider JP (2009) Expensive cancer drugs: A comparison between the United States and the United Kingdom. Milbank Q 87(4): 789-819.
9. Foot C, Harrison T (2011) How to Improve Cancer Survival, Explaining England's Relatively Poor Rates. The King's Fund and Cancer Research UK: Cavendish Square, London.
10. Ford J (2013) The NHS is facing a deepening financial crisis. BMJ 347: 4422.
11. Howell J (2011) Return of the postcode lottery. Opportunity cost of the Cancer Drugs Fund. Brit Med J 342: D622.
12. Hughes DA (2011) Value-based pricing incentive for innovation or zero net benefit?. Pharmacoeconomics 29(9): 731-735.
13. Jonsson B, Wilking N (2007) Market uptake of new oncology drugs. Ann Oncol 18: 31-48.
14. Kim H, Kriebel D (2009) Regression models for public health surveillance data: A simulation study. Occup Environ Med 66(11): 733-739.
15. Kos M, Obradovic M, Mrhar A (2008) Accessibility to targeted oncology drugs in Slovenia and selected European countries. Eur J Cancer 44(3): 408-418.
16. Lichtenberg FR (2009) The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004. Econ Innovat New Technol 18(5): 407-428.
17. Linley WG, Hughes DA (2013) Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: A cross-sectional survey of 4118 adults in Great Britain. Health Econ 22(8): 948-964.
18. NHS England (2013a) 2013/14 NHS Standard Contract For Cancer: Chemotherapy (Adult). http://www.england.nhs.uk/wp-content/uploads/2013/06/b15-cancr-chemoth.pdf.
19. NHS England (2013b) New single drug fund list to bring fairer system for cancer patients. http://www.england.nhs.uk/2013/04/04/cdf/.
20. Office for National Statistics (2011) Mid-1971 to mid-2010 population estimates: United Kingdom; estimated resident population for constituent countries and regions in England. http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk-england-And-wales-scotlandand-northern-ireland/population-estimates-Timeseries-1971-To-currentyear/index.html.
21. Patel N, Adatia R, Mellemgaard A, Jack R, Moller H (2007) Variation in the use of chemotherapy in lung cancer. Brit J Cancer 96(6): 886-890.
22. Ragupathy R, Aaltonen K, Tordoff J, Norris P, Reith D (2012) A 3-Dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics 30(11): 1051-1065.
23. Rarer Cancers Foundation (2011a) Exceptional Cymru?. An audit of the progress made in improving access to treatment for people with rarer cancers in Wales. http://www.rarercancers.org.uk/images/stories/cdf/p8and9/exceptional%20cymru%20-%20april%202011.pdf.
24. Rarer Cancers Foundation (2011b) Funding Cancer Drugs, an evaluation of the impact of policies to improve access to cancer treatments. http://www.rarercancers.org/images/stories/news/pdf/0611/funding-cancer-drugs-final.pdf.
25. Rarer Cancers Foundation (2011c) Nations Divided?. An assessment of variations in access to cancer treatments for patients in England, Scotland and Wales. http://www.rarercancers.org/images/stories/news/8011/nations-divided-final-complete-report.pdf.
26. Richards M (2004) Variations in usage of cancer drugs approved by NICE Report of the review undertaken by the National Cancer Director, Crown Copyright: Department of Health.
27. Richards M (2010) Extent and causes of international variations in drug usage. Department of Health, Crown Copyright.
28. Stanton M (2010) The Cancer Drugs Fund: A consultation. London: Department of Health, Crown Copyright.
29. Stephens P, Thomson D (2012) The Cancer Drug Fund 1 year on-success or failure?. Lancet Oncol 13(8): 754-757.
30. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12(10): 933-980.
31. The Information Centre for Health and Social Care (2012) Hospital prescribing England, In The Health and Social Care Information Centre. Vol. 2013.
32. Thornton S (2011) Return of the postcode lottery Cancer Drugs Fund is not a fair allocation of NHS resources. Br Med J 342: D621.
33. Verma S, Sehdev S, Joy AA (2007) Cancer therapy disparity: Unequal access to breast cancer therapeutics and drug funding in Canada. Curr Oncol 14(Suppl 1): S3-S10.
34. Wilking N, Jonsson B (2005) A Pan-European Comparison Regarding Patient Access to Cancer Drugs. Karolinska Institutet in collaboration with Stockholm School of Economics: Stockholm, Sweden.